About Alpha-1-antitrypsin
Alpha-1-antitrypsin (SERPINA1) is a protein
from Homo sapiens identified by UniProt accession
P01009, 418 residues long.
MolForge cross-references it against 0 known binders and
1,102 disease associations.
Target properties
| Protein name | Alpha-1-antitrypsin |
| UniProt accession | P01009 |
| Gene | SERPINA1 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (1102)
Diseases linked to this target (Open Targets).
- Alpha-1-antitrypsin deficiency · score 0.71
- alpha 1-antitrypsin deficiency · score 0.60
- chronic obstructive pulmonary disease · score 0.59
- blood protein measurement · score 0.50
- serum albumin measurement · score 0.50
- sex hormone-binding globulin measurement · score 0.50
- genetic disorder · score 0.49
- platelet count · score 0.48
- testosterone measurement · score 0.48
- refractive error measurement · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01009-F1 | alphafold | PREDICTED | 88.60 | — |
Amino-acid sequence (418 residues)
MPSSVSWGIL LLAGLCCLVP VSLAEDPQGD AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS LYRQLAHQSN STNIFFSPVS IATAFAMLSL GTKADTHDEI LEGLNFNLTE IPEAQIHEGF QELLRTLNQP DSQLQLTTGN GLFLSEGLKL VDKFLEDVKK LYHSEAFTVN FGDTEEAKKQ INDYVEKGTQ GKIVDLVKEL DRDTVFALVN YIFFKGKWER PFEVKDTEEE DFHVDQVTTV KVPMMKRLGM FNIQHCKKLS SWVLLMKYLG NATAIFFLPD EGKLQHLENE LTHDIITKFL ENEDRRSASL HLPKLSITGT YDLKSVLGQL GITKVFSNGA DLSGVTEEAP LKLSKAVHKA VLTIDEKGTE AAGAMFLEAI PMSIPPEVKF NKPFVFLMIE QNTKSPLFMG KVVNPTQK
Explore Alpha-1-antitrypsin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets